| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
114 companies · Health Care
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | UTHR United Therapeutics Corporation | Rothblatt Martine A | Chairperson &CEO | Sell | 4,160 | $544.19 | $2,263,831.55 | -22.4% | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, INC. | Boyd Peter E. | Chief People Officer | Sell | 29,814 | $4.17 | $124,413.82 | -8.1% | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, INC. | Jung Cassie | Chief Operating Officer | Sell | 45,791 | $4.17 | $191,085.84 | -14.3% | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, INC. | Braender Lori J | Chief Legal Officer | Sell | 40,102 | $4.17 | $167,345.65 | -8.3% | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, INC. | Korczynski Sherry | Chief Commercial Officer | Sell | 15,741 | $4.17 | $65,687.19 | -6.1% | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, INC. | Barber Daniel | President And CEO | Sell | 180,677 | $4.17 | $753,965.12 | -15.2% | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, INC. | Cioffi Melina | SVP, Regulatory Affairs | Sell | 25,311 | $4.17 | $105,622.80 | -8.4% | |
| Mar 10, 2026 | AQST Aquestive Therapeutics, INC. | Toth A Ernest Jr | Chief Financial Officer | Sell | 58,254 | $4.17 | $243,093.94 | -13.4% | |
| Mar 9, 2026 | INDV Indivior Pharmaceuticals, INC. | Ryan Barbara | Director | Buy | 31 | $32.56 | $1,009.36 | +0.5% | |
| Mar 9, 2026 | ORGO Organogenesis Holdings INC. | Leibowitz Arthur S | Director | Buy | 5,000 | $2.68 | $13,405.00 | +1.7% | |
| Mar 9, 2026 | COLL Collegium Pharmaceutical, INC. | Dieter David | EVP &General Counsel | Sell | 6,224 | $36.65 | $228,109.60 | -6.4% | |
| Mar 9, 2026 | ORGO Organogenesis Holdings INC. | Driscoll Michael Joseph | Director | Buy | 10,000 | $2.67 | $26,688.00 | +4.6% | |
| Mar 9, 2026 | LQDA Liquidia Corporation | Moomaw Scott | Chief Commercial Officer | Sell | 80,000 | $35.32 | $2,825,824.00 | -29.7% | |
| Mar 9, 2026 | KNSA Kiniksa Pharmaceuticals International, PLC | Ragosa Mark | Chief Financial Officer | Sell | 36,722 | $45.92 | $1,686,157.82 | -46.1% | |
| Mar 6, 2026 | PLNH Planet 13 Holdings INC. | Wren Chris | VP Of Operations | Sell | 30,000 | $0.16 | $4,854.00 | -0.7% | |
| Mar 6, 2026 | INDV Indivior Pharmaceuticals, INC. | Kingsley Stuart A | Director | Buy | 940 | $31.87 | $29,953.10 | +20.2% | |
| Mar 5, 2026 | UTHR United Therapeutics Corporation | Mahon Paul A | EVP &General Counsel | Sell | 368 | $479.43 | $176,429.17 | -0.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.